Which medications in the drug class Antineoplastics, Monoclonal Antibody are used in the treatment of Sjogren Syndrome?

Updated: Mar 05, 2021
  • Author: Sriya K Ranatunga, MD, MPH; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Antineoplastics, Monoclonal Antibody

Rituximab has a promising effect in the treatment of patients with severe extraglandular manifestations of Sjögren syndrome. Although some data support its efficacy for glandular involvement, it is not currently used for the treatment of sicca symptoms alone. Rituximab has an off-label indication for Sjögren syndrome.

Rituximab (Rituxan)

Rituximab is a monoclonal antibody directed against the CD20 antigen on maturing B-lymphocytes, leading to the depletion of mature circulating B-cells, which are believed to play an important role in the pathophysiology of primary Sjögren syndrome.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!